Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Operating Activities | – | – | – |
| Net Income | -$67,995 | -$51,985 | -$37,845 |
| Dep. & Amort. | $56 | $19 | $10 |
| Deferred Tax | $0 | $0 | $0 |
| Stock-Based Comp. | $7,397 | $1,899 | $810 |
| Change in WC | -$14,132 | -$9,624 | $4,949 |
| Other Non-Cash | -$77 | $14,063 | $0 |
| Operating Cash Flow | -$74,751 | -$45,628 | -$32,076 |
| Investing Activities | – | – | – |
| PP&E Inv. | -$71 | -$586 | -$192 |
| Net Acquisitions | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 |
| Other Inv. Act. | $62 | $0 | $0 |
| Investing Cash Flow | -$9 | -$586 | -$192 |
| Financing Activities | – | – | – |
| Debt Repay. | $0 | $0 | $0 |
| Stock Issued | $332,427 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 |
| Other Fin. Act. | $1,604 | $272,496 | $31,695 |
| Financing Cash Flow | $334,031 | $272,496 | $31,695 |
| Forex Effect | $0 | $0 | $0 |
| Net Chg. in Cash | $259,271 | $226,282 | -$573 |
| Supplemental Information | – | – | – |
| Beg. Cash | $230,440 | $4,158 | $4,731 |
| End Cash | $489,711 | $230,440 | $4,158 |
| Free Cash Flow | -$74,822 | -$46,214 | -$32,268 |